Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype

The study investigates proteomic predictors of response to baricitinib, a Janus kinase inhibitor, in patients with severe alopecia areata (AA). The research identifies CCL11 as a potential marker for a refractory phenotype, indicating that patients with higher levels of CCL11 may not respond well to baricitinib treatment. This finding could help in predicting which patients are less likely to benefit from baricitinib, allowing for more personalized treatment approaches in managing severe AA. The study emphasizes the need for further research to validate these findings and improve therapeutic strategies for alopecia areata.